true
0001549084
0001549084
2025-11-05
2025-11-05
0001549084
dei:FormerAddressMember
2025-11-05
2025-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 5, 2025
CHRONOSCALE
CORPORATION
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-37854 |
|
99-0367049 |
(State
or other jurisdiction
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
Number) |
3811
Turtle Creek Blvd. Suite 2100
Dallas,
Texas |
|
75219 |
| (Address
of registrant’s principal executive office) |
|
(Zip
code) |
214-427-1704
(Registrant’s
telephone number, including area code)
Ekso
Bionics Holdings, Inc.
101
Glacier Point, Suite A
San
Rafael, CA 94901
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
CHRN |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
This
Amendment to the Current Report on Form 8-K filed by Ekso Bionics Holdings, Inc. (n/k/a ChronoScale Corporation, the “Company”)
with the Securities and Exchange Commission (the “SEC”) on November 5, 2025, amends and supplements the disclosure with respect
to the phantom performance-based stock unit awards (“Phantom PSUs”) previously granted to Messrs. Scott G. Davis, Jerome
Wong and Jason Jones.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
November 5, 2025, the Board of Directors of the Company (the “Board”) granted the following Phantom PSUs under the Ekso Bionics
Holdings, Inc. Amended and Restated 2014 Equity Incentive Plan, as amended (the “2014 Plan”): 185,000 Phantom PSUs to Mr.
Davis, 40,000 Phantom PSUs to Mr. Wong and 32,000 Phantom PSUs to Mr. Jones (collectively, the “Phantom PSU Awards” and each,
a “Phantom PSU Award”). The Phantom PSU Awards were subject to vesting based on each grantee’s continued employment
through both the occurrence of a Change in Control (as defined in the 2014 Plan) and the achievement of the applicable Stock Price Goal
(as defined in the applicable Phantom PSU Award agreement), in each case on or prior to the fifth anniversary of the grant date. The
Phantom PSU Awards also provided for settlement entirely in cash.
On
May 14, 2026, the Board, acting as administrator under the 2014 Plan, determined that the applicable Stock Price Goal set forth in the
Phantom PSU Awards had been achieved, that the transactions contemplated by that certain Contribution and Exchange Agreement, dated February
15, 2026 (filed with the SEC as Exhibit 10.1 to the Company’s Current Report on Form 8-K on February 17, 2026), which closed on
May 5, 2026 (the “Closing”), constituted a Change in Control under the Phantom PSU Awards and the 2014 Plan, and that
the grantees had remained continuously employed through the achievement of the Stock Price Goal and the occurrence of the Change in Control.
In addition, the Board amended the settlement terms in each of the Phantom PSU Awards to replace cash-only settlement with the settlement
terms described below.
As
amended, Mr. Davis’s Phantom PSU Award settles in the form of a combination of shares of the Company’s common stock, par
value $0.001 per share (the “Common Stock”) and a cash payment, as follows: (i) 109,357 vested shares of Common Stock, and
(ii) $1,000,000 in cash (representing the balance of Mr. Davis’s Phantom PSU Award, or 75,643 Phantom PSUs). As amended, Mr. Wong’s
and Mr. Jones’s Phantom PSU Awards will each be settled exclusively in the form of shares of Common Stock, in the
amount of 40,000 shares of Common Stock for Mr. Wong, and 32,000 shares of Common Stock for Mr. Jones. In accordance with the terms
of the agreements evidencing the Phantom PSU Awards, as amended, the cash payment to Mr. Davis, and the issuance of shares of Common
Stock to each of Messrs. Davis, Wong, and Jones, will be made as soon as administratively practicable following the Closing, but in no
event later than March 15, 2027.
Except
as described in this Item 5.02, the terms of the Phantom PSU Awards granted to Messrs. Davis, Wong and Jones on November 5, 2025 are
unchanged and remain in full force and effect.
The
foregoing descriptions of the amendments to the Phantom PSU Awards are not complete and are qualified in their entirety by reference
to the full text of the Amendments to the Phantom Performance-Based Restricted Stock Unit Award Agreements, copies of which are filed
as Exhibits 10.1, 10.2, and 10.3 hereto.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit |
|
Description |
| 10.1* |
|
Amendment
to Phantom Performance-Based Restricted Stock Unit Award Agreement, dated May 20, 2026 by and between ChronoScale Corporation
and Scott G. Davis |
| 10.2* |
|
Amendment
to Phantom Performance-Based Restricted Stock Unit Award Agreement, dated May 20, 2026 by and between ChronoScale Corporation
and Jerome Wong |
| 10.3* |
|
Amendment
to Phantom Performance-Based Restricted Stock Unit Award Agreement, dated May 20, 2026 by and between ChronoScale Corporation
and Jason Jones |
| 104 |
|
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 10.1, 10.2 and 10.3). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
May 20, 2026
| |
CHRONOSCALE
CORPORATION |
| |
|
| |
By: |
/s/
Ying Cenly Chen |
| |
Name: |
Ying
Cenly Chen |
| |
Title: |
Chief
Executive Officer |